Get to Know Dr. Perry Shen
Dr. Perry Shen is a surgical oncologist specializing in the treatment of complex abdominal malignancies, including mesothelioma. He utilizes the novel combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC, to extend lives significantly.
Shen treats pancreatic, liver, gall bladder, colorectal and peritoneal diseases, including peritoneal mesothelioma cancer. He approaches each patient, each surgery, with a passionate determination to win.
“I look at it like a general going to war, making a plan, then doing this complex and challenging operation to improve that patient’s survival and quality of life,” he said. “I’m always looking for the ultimate treatment for each patient.”
As a mesothelioma specialist, much of Shen’s research at Wake Forest has centered around improving the lives of patients diagnosed with peritoneal mesothelioma, most often caused by an exposure to asbestos.
He co-authored a recent retrospective study looking at the considerable benefits of repeating the HIPEC procedure after a cancer recurrence for those with various abdominal malignancies.
Shen also serves as a professor of surgical sciences at Wake Forest University School of Medicine and runs marathons in his spare time.
Specialties of Dr. Perry Shen
- Cytoreductive surgery
- Laparoscopic distal pancreatectomy
- Whipple procedure
- Radiofrequency ablation
- Colorectal cancer
- Peritoneal mesothelioma cancer
- Liver cancer
- Gall bladder surgery
- Gastrointestinal disease
Dr. Perry Shen’s Experience and Medical Education
- Wake Forest Baptist Health Comprehensive Cancer Center
- John Wayne Cancer Institute (Fellowship)
- Johns Hopkins Hospital (Residency)
- University of Southern California School of Medicine (M.D.)
Awards and Certifications
- America’s Top Doctors for Cancer, Castle Connolly
- American Board of Surgery
- American College of Surgeons
- North Carolina Medical Association
- American Hepato-Pancreato-Biliary Association
Publications of Dr. Perry Shen
- Valenzuela, C.D. et al. (2022, March 7). Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis – A 30-year Institutional Experience. Annals of Surgical Oncology.
- Enomoto, L.M. et al. (2020, January). Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risks Primary Appendiceal Neoplasms After Complete Resection. Annals of Surgical Oncology.
- Ali, Y.M. et al. (2020, January). Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. Annals of Surgical Oncology.
- Enomoto, L.M. et al. (2019, May 7). Cytoreductive Surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Management and Research.
Thank you for your feedback. Would you like to speak with a Patient Advocate?